Lantern Pharma

Lantern Pharma reported Phase 1a data for LP-184 (zirdafulven) in recurrent glioblastoma and set an expansion dose of 0.39 mg/kg. Because only about 20% of systemic drug is expected to reach brain tumors, single-agent brain concentrations are not projected to stay at therapeutic levels, so the company plans a Phase 1b/2a trial combining LP-184 with spironolactone, which degrades the DNA repair protein ERCC3. In preclinical models, spironolactone lowered the LP-184 concentration needed to kill tumor cells 3- to 6-fold.

Lantern Pharma reported Phase 1a data for LP-184 (zirdafulven) in recurrent glioblastoma and set an expansion dose of 0.39 mg/kg. Because only about 20% of systemic drug is expected to reach brain tumors, single-agent brain concentrations are not projected to stay at therapeutic levels, so the company plans a Phase 1b/2a trial combining LP-184 with spironolactone, which degrades the DNA repair protein ERCC3. In preclinical models, spironolactone lowered the LP-184 concentration needed to kill tumor cells 3- to 6-fold.